Skip to main content

LUNG FUNCTION IMPROVEMENT IN PATIENTS 12+ YEARS

Open Up a World
Where Patients Can Feel Breathing Relief

See how DUPIXENT can improve lung function in your patients1

Open Up a World
WHERE PATIENTS CAN FEEL BREATHING RELIEF

See how DUPIXENT can improve lung function in your patients1

DUPIXENT provided rapid lung function improvement patients can feel as early as Week 21-3

Lung function improvement through Week 521,3

Baseline blood EOS ≥300 cells/μL (QUEST, secondary endpoint)

QUEST primary endpoint results (ITT population)

  • 320 mL improvement from baseline in pre-bronchodilator FEV1 at Week 12 with DUPIXENT 200 mg Q2W + SOC (n=633) vs 180 mL with placebo + SOC (n=317) (LSM difference: 140 mL [95% CL: 80, 190 mL]) 1,4
  • 340 mL improvement from baseline in pre-bronchodilator FEV1 at Week 12 with DUPIXENT 300 mg Q2W + SOC (n=633) vs 210 mL with placebo + SOC (n=321) (LSM difference: 130 mL [95% CL: 80, 180 mL])1,4

480 mL improvement from baseline in pre-bronchodilator FEV1 at Week 52 with DUPIXENT 300 mg Q2W + SOC (n=277) vs 230 mL with placebo + SOC (n=142) (baseline blood EOS ≥300 cells/μL, QUEST, secondary endpoint).1

In QUEST, a significant difference from placebo + SOC was not observed at 12 weeks in change in pre-bronchodilator FEV1 in patients with baseline blood EOS ≥150 to <300 cells/μL taking DUPIXENT 300 mg Q2W + SOC and in patients with baseline blood EOS <150 cells/μL taking DUPIXENT 200 mg Q2W or 300 mg Q2W + SOC.1

DUPIXENT sustained lung function improvement for up to 3 years4,a,b

Up to ~3 years of breathing relief2,4

  • 310 mL improvement in FEV1 at Week 96 in the DUPIXENT/DUPIXENT group (n=447) from 1.78 L at baseline in the parent study
    for patients enrolled from QUEST (overall exposed population, TRAVERSE OLE study, secondary endpoint)4
    • 330 mL improvement in FEV1 at Week 96 in the placebo/DUPIXENT group (n=219) from 1.75 L at baseline in the parent
      study for patients enrolled from QUEST4

Results are descriptive. Definitive conclusions cannot be made.

Data were not multiplicity controlled and there are limitations associated
with open-label study design, including lack of comparator arm, decreasing
sample size, and potential continued involvement of responders and
attrition of nonresponders.

a1.78 L was the baseline FEV1 level from QUEST (n=633) compared with a
placebo value of 1.75 L (n=321).4

bFEV1 was assessed in the exposed population (observed cases) using
descriptive statistics.5

Not actual DUPIXENT patients.

Some adult patients felt their asthma symptoms improve
in as little as 3 days6

LSM difference between combined DUPIXENT 200 mg and 300 mg Q2W (n=916) and combined placebos (n=475) in change from baseline were
observed by Day 3 (−0.08 [95% Cl: −0.15, −0.01]).6

Based on patients’ morning symptom diaries in a post hoc analysis of five phase 3 studies on AD, asthma, and CRSwNP. Results are descriptive.
Definitive conclusions cannot be made.

Lung function improvement in patients 12+ years across EOS
levels at Week 521,3,4


PATIENTS WITH ELEVATED EOS (QUEST, post hoc analysis)3,4

Results are descriptive. Definitive conclusions cannot be made as this was a post-hoc analysis. There are limitations on sample size and data
were not multiplicity controlled. DUPIXENT trials enrolled patients with EOS levels up to 1500 cells/μL.1


PATIENTS WITH ELEVATED EOS +
ALLERGIC ASTHMA (QUEST, post hoc
analysis)4

Results are descriptive. Definitive conclusions cannot be made as this was a post-hoc analysis. There are limitations on sample size and data
were not multiplicity controlled. Allergic asthma was defined as total serum IgE ≥30 IU/mL + ≥1 positive perennial-aeroallergen–specific IgE ≥0.35 kU/L at baseline.8

AD, atopic dermatitis; CRSwNP, chronic rhinosinusitis with nasal polyps; EOS, eosinophils; FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; ITT, intention-to-treat; LSM, least squares mean; OLE, open-label extension; Q2W, once every 2 weeks; SOC, standard of care.

DUPIXENT provided rapid lung function improvement patients can feel as early as Week 22,4

Lung function improvement through Week 524

Baseline blood EOS ≥300 cells/μL (QUEST, post hoc analysis)

  • 500 mL improvement from baseline in pre-bronchodilator FEV1 at Week 52 with DUPIXENT 300 mg Q2W + SOC (n=129) vs 250 mL with
    placebo + SOC (n=61) (LSM difference: 250 mL [95% CI: 110, 390 mL])4

Results are descriptive. Definitive conclusions cannot be made as this was a post hoc analysis. There are limitations on sample
size and data were not multiplicity controlled.

DUPIXENT sustained lung function improvement for up to 3 years4,c,d

Up to ~3 years of breathing relief2,4

  • 450 mL improvement in FEV1 at Week 96 in the DUPIXENT/DUPIXENT group (n=92) from 1.84 L at baseline
    in the parent study for patients enrolled from QUEST (baseline blood EOS ≥300 cells/μL, TRAVERSE OLE
    study, post hoc analysis)4
    • 440 mL improvement in FEV1 at Week 96 in the placebo/DUPIXENT group (n=50)
      from 1.89 L at baseline in the parent study for patients enrolled from QUEST4

Results are descriptive. Definitive conclusions cannot be made as this was
a post hoc analysis of open-label extension data.

Data were not multiplicity controlled and there are limitations associated
with open-label study design, including lack of comparator arm, decreasing
sample size, and potential continued involvement of responders and
attrition of nonresponders.

c1.84 L was the baseline FEV1 level from QUEST (n=129) compared with a
placebo value of 1.89 L (n=61).4

dFEV1 was assessed in the exposed population (observed cases) using
descriptive statistics.5

EOS, eosinophils; FEV1, forced expiratory volume in 1 second; ICS, inhaled
corticosteroid; LSM, least squares mean; OLE, open-label extension;
Q2W, once every 2 weeks; SOC, standard of care.

Not actual DUPIXENT patients.

Explore the SAFETY
DATA AND STUDY DESIGNS

VIEW safety data SEE THE FULL STUDY DESIGNS

Dosage and Administration

See the multiple dosage and administration options for patients on DUPIXENT.

EXPLORE ADMINISTRATION OPTIONS